Cargando…
Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature
Hepatocellular carcinoma, one of the most dreaded complications of cirrhosis, is a frequent cancer with high mortality. Early primary liver cancer can be treated by surgery or ablation techniques, but advanced hepatocellular carcinoma remains a challenge for clinicians. Most of these patients have u...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801667/ https://www.ncbi.nlm.nih.gov/pubmed/31569719 http://dx.doi.org/10.3390/ijms20194811 |
_version_ | 1783460629846163456 |
---|---|
author | Reynaert, Hendrik Colle, Isabelle |
author_facet | Reynaert, Hendrik Colle, Isabelle |
author_sort | Reynaert, Hendrik |
collection | PubMed |
description | Hepatocellular carcinoma, one of the most dreaded complications of cirrhosis, is a frequent cancer with high mortality. Early primary liver cancer can be treated by surgery or ablation techniques, but advanced hepatocellular carcinoma remains a challenge for clinicians. Most of these patients have underlying cirrhosis, which complicates or even precludes treatment. Therefore, efficacious treatments without major side effects are welcomed. Initial results of treatment of advanced hepatocellular carcinoma with somatostatin analogues were promising, but subsequent trials have resulted in conflicting outcomes. This might be explained by different patient populations, differences in dosage and type of treatment and differences in somatostatin receptor expression in the tumor or surrounding tissue. It has been shown that the expression of somatostatin receptors in the tumor might be of importance to select patients who could benefit from treatment with somatostatin analogues. Moreover, somatostatin receptor expression in hepatocellular carcinoma has been shown to correlate with recurrence, prognosis, and survival. In this review, we will summarize the available data on treatment of primary liver cancer with somatostatin analogues and analyze the current knowledge of somatostatin receptor expression in hepatocellular carcinoma and its possible clinical impact. |
format | Online Article Text |
id | pubmed-6801667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68016672019-10-31 Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature Reynaert, Hendrik Colle, Isabelle Int J Mol Sci Review Hepatocellular carcinoma, one of the most dreaded complications of cirrhosis, is a frequent cancer with high mortality. Early primary liver cancer can be treated by surgery or ablation techniques, but advanced hepatocellular carcinoma remains a challenge for clinicians. Most of these patients have underlying cirrhosis, which complicates or even precludes treatment. Therefore, efficacious treatments without major side effects are welcomed. Initial results of treatment of advanced hepatocellular carcinoma with somatostatin analogues were promising, but subsequent trials have resulted in conflicting outcomes. This might be explained by different patient populations, differences in dosage and type of treatment and differences in somatostatin receptor expression in the tumor or surrounding tissue. It has been shown that the expression of somatostatin receptors in the tumor might be of importance to select patients who could benefit from treatment with somatostatin analogues. Moreover, somatostatin receptor expression in hepatocellular carcinoma has been shown to correlate with recurrence, prognosis, and survival. In this review, we will summarize the available data on treatment of primary liver cancer with somatostatin analogues and analyze the current knowledge of somatostatin receptor expression in hepatocellular carcinoma and its possible clinical impact. MDPI 2019-09-27 /pmc/articles/PMC6801667/ /pubmed/31569719 http://dx.doi.org/10.3390/ijms20194811 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Reynaert, Hendrik Colle, Isabelle Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature |
title | Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature |
title_full | Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature |
title_fullStr | Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature |
title_full_unstemmed | Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature |
title_short | Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature |
title_sort | treatment of advanced hepatocellular carcinoma with somatostatin analogues: a review of the literature |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801667/ https://www.ncbi.nlm.nih.gov/pubmed/31569719 http://dx.doi.org/10.3390/ijms20194811 |
work_keys_str_mv | AT reynaerthendrik treatmentofadvancedhepatocellularcarcinomawithsomatostatinanaloguesareviewoftheliterature AT colleisabelle treatmentofadvancedhepatocellularcarcinomawithsomatostatinanaloguesareviewoftheliterature |